Geoffrey Alan Watson

Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer

Geoffrey Alan Watson, Oana Deac, Razia Aslam et al. · Clinical Breast Cancer · 2018 · 36 citations

Breast Oncology, Oncology, Real-world Experience +10

Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab

Geoffrey Alan Watson, Enrique Sanz‐García, Wenjiang Zhang et al. · Journal for ImmunoTherapy of Cancer · 2022 · 23 citations · Full text

A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events

Helena J. Janse van Rensburg, Zhihui Liu, Geoffrey Alan Watson et al. · British Journal of Cancer · 2023 · 15 citations · Full text

Toxicities in immunotherapy: Can they predict response?

Lisa Prior, Emily Harrold, Connor O’Leary et al. · Journal of Clinical Oncology · 2016 · 13 citations

Immunotoxicology, Immunology, Immunoediting +20

Progressive multifocal leukoencephalopathy secondary to rituximab-induced immunosuppression and the presence of John Cunningham virus: a case report and literature review

Deirdre Kelly, Bernadette Monaghan, Eileen M. McMahon et al. · Radiology Case Reports · 2016 · 12 citations · Full text